GLP-1 Agonist Polypeptide Composition for Proteolytic Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current GLP-1 analogs for treating type 2 diabetes suffer from limited efficacy due to side effects such as nausea and vomiting, and they have a single mechanism of action that does not fully address glycemic control and weight loss, while native GLP-1 and GIP are rapidly inactivated by DPP IV, limiting their metabolic control.
Innovation Solution
Development of GLP-1 agonist polypeptide compounds with dual action mechanisms, incorporating unnatural amino acids to enhance proteolytic stability and incorporating a fatty acid chain for improved pharmacokinetics, synthesized using a solid-phase method and reversed phase chromatography.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If GLP-1 analogs are administered at higher doses to achieve full efficacy in glycemic control and weight loss, then hypoglycemic activity and weight loss effect are improved, but side effects such as nausea and vomiting worsen
Solution Approach 1:
The patent modifies the molecular structure of GLP-1 analogs by incorporating unnatural amino acids and fatty acid chains, changing the chemical parameters of the compound. These structural modifications enable the peptide to resist DPP IV degradation while maintaining receptor binding affinity, thereby achieving sustained therapeutic effects at lower doses without exacerbating side effects
Solution Approach 2:
The invention creates composite peptide structures by combining natural amino acid sequences with unnatural amino acids and fatty acid moieties. This composite approach produces a hybrid molecule that simultaneously achieves proteolytic stability, prolonged circulation half-life, and sustained GLP-1 receptor activation, resolving the contradiction between efficacy and side effects
2Adaptability or versatility
If native GIP and GLP-1 are used for metabolic control, then dual mechanism of action is achieved, but proteolytic stability deteriorates due to rapid inactivation by DPP IV
Solution Approach 1:
The patent systematically modifies the peptide sequence by replacing specific natural amino acids with unnatural variants at strategic positions. These parameter changes confer resistance to DPP IV cleavage while preserving the dual incretin activity, thereby achieving both stability and versatility simultaneously
Solution Approach 2:
The invention extracts the essential functional domains of GIP and GLP-1 that confer dual mechanism of action, while removing or modifying the vulnerable regions that are susceptible to DPP IV degradation. This selective extraction and reconstruction approach maintains therapeutic activity while eliminating proteolytic vulnerability
3Stability of the object's composition
If unnatural amino acids are introduced into the peptide sequence to increase proteolytic stability, then stability against DPP IV is improved, but manufacturing complexity worsens
Solution Approach 1:
The patent optimizes the selection and placement of unnatural amino acids to achieve maximum proteolytic stability with minimal structural modifications. By carefully controlling the number and position of non-natural residues, the invention balances stability enhancement against manufacturing feasibility
Solution Approach 2:
The invention employs solid-phase peptide synthesis as an intermediary manufacturing approach that facilitates the incorporation of unnatural amino acids. This synthesis method enables systematic introduction of modified residues through standardized coupling reactions, thereby reducing the complexity burden despite the use of non-natural building blocks
4Ease of operation
If GLP-1 analogs are designed for once-weekly dosing to improve patient compliance, then dosing frequency is reduced, but in vivo stability requirements worsen
Solution Approach 1:
The patent incorporates fatty acid chains into the GLP-1 analog structure, creating composite molecules that bind to albumin in circulation. This composite structure protects the peptide from rapid clearance and extends half-life from minutes to days, enabling once-weekly dosing while maintaining sustained therapeutic levels
Solution Approach 2:
The invention implements excessive proteolytic stability by designing peptides that are far more resistant to degradation than minimally required. This excessive stability ensures that sufficient drug levels are maintained throughout the week-long dosing interval, accounting for physiological variations and ensuring consistent therapeutic effect
Data Source
AI summary
The disclosure provides a GLP-1 agonist polypeptide compound having an amino acid sequence: H Xaa1EGTFTSDVSSYLE Xaa2QAA Xaa3EFIAWLVRGRG (SEQ ID NO: 1). The C-terminal amino acid of the polypeptide compound is a carboxyl or the carboxyl is amidated. Xaa1 and Xaa2 are the same or different; R1 is: a straight-chain or branched-chain alkyl containing 2-6 carbon atoms, R2 is: H or CH3, X is: O, S or N—CH3, in the formula, R1 and R2 alkyl is optionally substituted by 1-6 halogen atoms.